1. Home
  2. MSGY vs CTXR Comparison

MSGY vs CTXR Comparison

Compare MSGY & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MSGY

Masonglory Limited Ordinary Shares

N/A

Current Price

$2.83

Market Cap

24.0M

Sector

N/A

ML Signal

N/A

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$1.18

Market Cap

19.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSGY
CTXR
Founded
2018
2007
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.0M
19.8M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
MSGY
CTXR
Price
$2.83
$1.18
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
1.7M
595.9K
Earning Date
12-12-2025
12-26-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$23,318,482.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$27.08
N/A
Revenue Growth
13.04
N/A
52 Week Low
$0.83
$0.65
52 Week High
$22.20
$5.95

Technical Indicators

Market Signals
Indicator
MSGY
CTXR
Relative Strength Index (RSI) N/A 46.75
Support Level N/A $1.12
Resistance Level N/A $1.54
Average True Range (ATR) 0.00 0.14
MACD 0.00 0.01
Stochastic Oscillator 0.00 42.04

Price Performance

Historical Comparison
MSGY
CTXR

About MSGY Masonglory Limited Ordinary Shares

Masonglory Ltd is a a holding company and operates through subsidiary. It is engaged in the provision of wet trades services and other ancillary services as a subcontractor in Hong Kong. As a subcontractor, It provide customers with comprehensive wet trades works solutions, which principally include plastering on floors, ceilings and walls, tile laying on internal and external walls and floors, brick laying, floor screeding, and marble works.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: